KANGSTEM BIOTECH Co., Ltd.

As of June 30, 2026, KANGSTEM BIOTECH Co., Ltd. carries a market capitalization of 215.38B, placing it among publicly traded companies globally. Its enterprise value stands at 197.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, KANGSTEM BIOTECH Co., Ltd. has 94.05M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 63.20, and the price-to-book ratio stands at 3.81.

These figures are as of June 30, 2026. The EV/Sales ratio of 66.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 197.16B versus a market cap of 215.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KANGSTEM BIOTECH Co., Ltd. maintains a current ratio of 3.96, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.24, indicating elevated leverage, while an interest coverage ratio of -35.63 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, KANGSTEM BIOTECH Co., Ltd. posted a negative return on equity (ROE) of -42.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.86, reflecting losses generated across the asset base. The company generates approximately 32.74M in revenue per employee across its workforce of 90.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.90 indicates how many times KANGSTEM BIOTECH Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, KANGSTEM BIOTECH Co., Ltd.'s stock has gained approximately 30.07% over the past 52 weeks. The 50-day moving average sits at 2,227.04, while the 200-day moving average is 2,572.65.

Over the twelve months ended June 30, 2026, KANGSTEM BIOTECH Co., Ltd. generated 2.96B in revenue and converted that into -20.09B in net income, yielding earnings per share of -245.66. EBITDA reached -17.53B, while operating income came in at -19.26B.

As of June 30, 2026, KANGSTEM BIOTECH Co., Ltd. holds 27.41B in cash and equivalents against 9.19B in total debt, resulting in a net debt position of 6.66B. Total book value stands at 56.56B, with working capital of 23.46B providing operational flexibility.

KANGSTEM BIOTECH Co., Ltd. produced -15.32B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -423.58M in capital expenditures, free cash flow totaled -15.74B - equivalent to -192.50 per share.

Over the twelve months ended June 30, 2026, KANGSTEM BIOTECH Co., Ltd. posted a gross margin of 6.74, reflecting its pricing power and cost economics. The operating margin of -650.16 and net profit margin of -677.98 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.29, meaning KANGSTEM BIOTECH Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

KANGSTEM BIOTECH Co., Ltd.'s most recent stock split took place on July 10, 2025 with a 455:544 split ratio.

As of June 30, 2026, KANGSTEM BIOTECH Co., Ltd. has an Altman Z-Score of 5.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.